Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accumulated Expenses: 2017-2025

Historic Accumulated Expenses for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $18.4 million.

  • Denali Therapeutics' Accumulated Expenses rose 23.42% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 23.42%. This contributed to the annual value of $24.7 million for FY2024, which is 63.90% down from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Accumulated Expenses is $18.4 million, which was up 52.12% from $12.1 million recorded in Q2 2025.
  • Denali Therapeutics' Accumulated Expenses' 5-year high stood at $68.5 million during Q4 2023, with a 5-year trough of $5.8 million in Q1 2022.
  • Its 3-year average for Accumulated Expenses is $18.0 million, with a median of $12.1 million in 2025.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first spiked by 250.77% in 2022, then tumbled by 63.90% in 2024.
  • Denali Therapeutics' Accumulated Expenses (Quarterly) stood at $19.0 million in 2021, then spiked by 250.77% to $66.7 million in 2022, then grew by 2.71% to $68.5 million in 2023, then crashed by 63.90% to $24.7 million in 2024, then rose by 23.42% to $18.4 million in 2025.
  • Its Accumulated Expenses was $18.4 million in Q3 2025, compared to $12.1 million in Q2 2025 and $7.7 million in Q1 2025.